Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind Pharmacokinetic Study Of Pf-05280014 Plus Taxotere (Registered) And Carboplatin Versus Herceptin (Registered) Plus Taxotere (Registered) And Carboplatin For The Neoadjuvant Treatment Of Patients With Operable Her2-positive Breast Cancer

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind Pharmacokinetic Study Of Pf-05280014 Plus Taxotere (Registered) And Carboplatin Versus Herceptin (Registered) Plus Taxotere (Registered) And Carboplatin For The Neoadjuvant Treatment Of Patients With Operable Her2-positive Breast Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary) ; Carboplatin; Docetaxel
  • Indications Early breast cancer; HER2 positive breast cancer
  • Focus Pharmacokinetics; Registrational
  • Acronyms REFLECTION B327-04; REFLECTIONS B327-04
  • Sponsors Pfizer

    • Most Recent Events

    • 12 Sep 2017 Results assessing pharmacokinetics, efficacy, immunogenicity and tolerability of neoadjuvant administration of two different trastuzumab formulations - trastuzumab biosimilar [PF-05280014] versus Herceptin, each with docetaxel and carboplatin, in female patients with HER2+ breast cancer, were presented at the 42nd European Society for Medical Oncology Congress.
    • 10 Sep 2017 Positive data from this supplemental study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, according to a Pfizer media release.
    • 30 Nov 2016 Primary endpoint has been met. (Percentage of patients with steady state drug concentration Cycle 5 Ctrough (Cycle 6 pre-dose) 20 g/mL between trastuzumab-Pfizer versus Herceptin)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top